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Promethazine Extravasation
By: Dawn Kruzan, PharmD candidate
Intravenous (IV) fluid extravasation is defined as a leakage of injectable
fluids out of the vein and into the interstitial space. This common problem may be due to a displacement of the IV line or from increased vascular permeability. Tissue may be damaged to varying degrees depending on the solution being injected. Some IV solutions may be irritants
(agents that stimulate an inflammatory response) or vesicants (blistering
agents that cause burns and destruction of tissue both internally and externally). The most common solutions to extravasate are cationic (eg,
potassium ion), osmotically active agents (eg, parenteral nutrition), antibiotics, or cytotoxic drugs. The
incidence is greatly increased in
children. Common sites of extravasation include the dorsum of
the hand in adults and the dorsum
of hand or scalp in neonates.
Newborns are at a higher risk because of their smaller, more fragile veins and their inability to verbalize pain.1
A commonly used medication that
can cause harm if extravasated is
promethazine (Phenergan®), a
vesicant with a pH between 4 and
5.5. It can cause severe tissue
damage, regardless of the route of
parenteral administration, though IV and inadvertent intra-arterial or
subcutaneous administration leads to more significant complications.
This damage may include pain, burning, swelling, erythema, severe
vessel spasm, thrombophlebitis, nerve damage, paralysis, phlebitis, abscess, venous thrombosis, tissue necrosis and gangrene. Surgical intervention may be required including fasciotomy, skin graft and amputation.2
In 2004, a professional musician was awarded $7.4 million after she
endured two amputation surgeries following accidental arterial admini-
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stration of promethazine. Initially
visiting the emergency department
suffering from a migraine, she received the dose of promethazine
and subsequently developed circulatory problems, followed by progressive gangrene which led to the
amputation of her arm.2
Because of these potential risks,
the product labeling states, “The
preferred parenteral route of administration for promethazine injection is by deep intramuscular
injection. The proper IV administration of this product is welltolerated, but use of this route is
not without some hazard. Not for
subcutaneous administration.”3
The Institute for Safe Medication
Practices (ISMP) recommends the
following strategies to prevent or
minimize tissue damage when administering IV promethazine.2,4,5
▪

▪

▪

▪

Limit concentration: The highest concentration of promethazine that can be given IV is
25 mg/mL. ISMP recommends
that hospitals stock only this concentration (not the 50 mg/mL
concentration).
Limit the dose: Consider 6.25 to
12.5 mg as the starting dose.
These smaller doses have proven
to be effective in many patients,
while reducing extravasation
risks.
Dilute the drug: Further dilution
in a running IV or in a mini bag
can reduce vesicant effects and
enable slow administration,
which can allow extravasation to
be recognized more quickly. For
example, dilute in 10 to 20 mL of
0.9% sodium chloride.
Use large patent veins: Give the
medication only through a large-

bore vein (preferably via central
access) and avoid hand or wrist
veins. Check patency of the
access site before administration.

▪

Inject into the farthest port:
Administer through a running
IV line at the port farthest from
the patient’s vein.

▪

Administer slowly: Consider
running over 10 to 15 minutes,
but with close monitoring for
extravasation effects.

▪

Revise orders: Revise preprinted orders to ensure orders
for promethazine reflect safety
measures.

▪

Educate patients: Before administration, tell patients to
alert a healthcare professional
immediately if they experience
burning or pain during or after
the injection.

▪

Create alerts: Each time a
dose of IV promethazine is accessed and administered, the
nurse should be reminded that
the drug is a vesicant and
should be diluted and administered slowly.

▪

▪

Use alternatives: Consider ondansetron, a serotonin receptor
antagonist that may be used for
both prophylaxis and as a rescue antiemetic.
Remove from formulary:
Some hospitals have banned IV
use of promethazine or removed the drug from the formulary.

There is no proven successful
management of unintentional
intra-arterial injection or perivascular extravasation after it occurs. Partial success has been
seen in case reports with elevation of the injection site, corti-

costeroid therapy, stellate ganglion blockade, and pain control.6
Other practitioners have used hyaluronidase, nitroglycerin ointment
or patch, or dimethyl sulfoxide
(DMSO). However, none of these
have been studied in promethazine
extravasation for which the effects
can be catastrophic and often irreversible.5,7-9
Here at MUSC, the IV push
guidelines specify an administration rate not to exceed 25 mg/min.
Promethazine must be diluted
with 10 to 20 mL of either 0.9%
sodium chloride or dextrose 5% in
water prior to administration. It
should be administered through a
large bore vein and the patency of
access should be checked before
administration. The adult IV push
medication administration guidelines can be found on the MUSC
Formulary and Drug Information
Resources Web page under the
Nursing and Pharmacy tabs.
(www.formularyproductions.com/musc )
Alerts are posted on the promethazine profile in the AcuDose-Rx™ cabinets and on the
MAR so that the nurse is reminded of the requirements prior
to administration.
References available upon request.
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Did You Know…
Automatic Therapeutic Substitution (ATS) at MUSC
With the rising costs of healthcare across the United States, hospital systems are looking for methods to decrease medication costs through better formulary management. The desire to decrease hospital expenditures,
though, must never overshadow the universal healthcare goal of maintaining patient safety. One common practice that is able to appease both goals of the healthcare system is therapeutic interchange (TI), also known as
automatic therapeutic substitution (ATS).
The American College of Clinical Pharmacy (ACCP) Guidelines for Therapeutic Interchange define TI as the
dispensing of a drug that is therapeutically equivalent to, but chemically different from, the drug originally
prescribed by a physician or other authorized prescriber. The use of therapeutic substitution has grown recently
because of an increase in the number of drugs within the same therapeutic class and the need to decrease
healthcare costs while providing high-quality standards of care.
In the ATS process, a pharmacist reviews a physician order and determines if a formulary substitution can be
made according to the appropriate protocol. Next, the pharmacist enters the order and documents “automatic
therapeutic substitution” in the inpatient pharmacy services computer system (eMeds). The pharmacist then
completes the documentation by adding a pre-printed automatic therapeutic substitution sticker to the patient’s
chart indicating the change of medication. Under computerized provider order entry (CPOE), a therapeutically
equivalent formulary alternative appears as a choice when a nonformulary medication that falls under an ATS
protocol is entered. If the prescriber does not chose the formulary alternative, the pharmacist will make the
conversion based on the protocol.
A mechanism does exist to bypass the ATS protocol if the prescriber deems a specific medication clinically
necessary. If the prescriber specifically wants a nonformulary medication, he or she must provide a clinical
justification and enter into the comments field or write “DAW” or “dispense as written” on the actual order.
The Pharmacy and Therapeutics Committee (P&T Committee) makes decisions concerning medications potentially appropriate for substitution. Currently, 16 protocols have been approved and implemented by the P&T
Committee. Recent changes among the ATS protocols include the addition of a new protocol for venlafaxine
(Effexor®) orders and the inclusion of bupropion hydrobromide (Aplenzin®) to the current bupropion protocol.
Future protocols may include conversions for angiotensin receptor blocking agents and the newly added carbapenem, doripenem (Doribax®). A list of current protocols can be found in the table below. Specific details
regarding each of the ATS protocols can be located on the MUSC Formulary and Drug Information Resources
Web page (www.formularyproductions.com/musc).

Table 1. MUSC Automatic Therapeutic Substitution Protocols
▪
▪
▪
▪
▪
▪
▪
▪

Albuterol/ipratropium nebulization solution (DuoNeb®)
Angiotensin converting enzyme (ACE) inhibitors
Bupropion (Wellbutrin® IR; Wellbutrin® XR; Aplenzin®)
Escitalopram (Lexapro®)
Ferrous sulfate products
Fluoroquinolone antibiotics
Fluticasone (Flovent® HFA) to
Beclomethasone (QVAR®)*
H2-antagonists

▪
▪
▪
▪
▪
▪
▪
▪

Insulin products (selected)
Intranasal steroids
Levalbuterol (Xopenex®)
Nonsedating antihistamines
Paliperidone (Invega®)
Polyethylene glycol (MiraLax®)
Proton pump inhibitors (PPIs)
Venlafaxine immediate release (Effexor®)
and extended release (Effexor® XR)

* Only for patients that require treatment while on mechanical ventilation, have a tracheotomy tube, or
require a large volume spacer
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FORMULARY UPDATE FOR JUNE & JULY 2009
In June and July 2009, the Pharmacy and Therapeutics Committee approved the actions listed
below. The changes are considered formulary effective unless
otherwise stated .

Additions:
Doripenem (Doribax®)
It was recommended that
doripenem be added to the formulary and meropenem be
RESTRICTED to the following
services/indications: pediatrics,
infectious diseases, hematology/oncology, and in those patients with suspected or documented meningitis. Guidelines for
doripenem dosing, as well as an
automatic therapeutic substitution
program will be developed and
implemented in the near future.
The projected effective date is
October 1, 2009.
500-mg vials

Sodium Phosphate (monobasic
monohydrate/ dibasic anhydrous)
[OsmoPrep®]
OsmoPrep® is a prescription product indicated for colonoscopy
preparation that has been proven
to be non-inferior to PEG electrolyte solutions (ie, Colyte ® ,
GoLYTELY®) and is preferred by
patients. Until smaller-volume,
oral NaP solutions become available, OsmoPrep® will be temporarily added to the formulary.
Tablets (Sodium phosphate monobasic
monohydrate 1.102 g, sodium phosphate dibasic anhydrous 0.398 g)

Benzocaine OSP 20%
(Dermoplast®)
Dermoplast® is indicated for the
temporary relief of pain and itch-

ing due to minor skin irritations.
It is also commonly used for the
relief of pain from episiotomy. It
is significantly cheaper than Epifoam®, and the addition of hydrocortisone offers no further
pain relief. Therefore, Dermoplast® was added for pain relief
from episiotomy, and Epifoam®
will be removed.
60-mL spray can

Esomeprazole (Nexium®)
Esomeprazole is indicated for
the treatment of acid-related
disorders in adults and pediatric
patients (>1 year). Esomeprazole
will be added to the formulary as
the proton pump inhibitor of
choice for all patient populations
(ie, adult, pediatric, neonate),
and pantoprazole, omeprazole,
and lansoprazole will be deleted.
The intravenous formulation will
be restricted per clinical
guidelines and the order form.
The automatic therapeutic
substitution protocol will be
updated to reflect this change.
The projected effective date is
October 1, 2009.
20- and 40-mg delayed-release
capsules, 10-, 20-, 40-mg
delayedrelease powder for
suspension, 20-, 40-mg injection

Hydroxyethyl starch 130/0.4 in
NS (Voluven®)
Hydroxyethyl starch 130/0.4 in
NS (Voluven®) is a volume
expander for the prevention/
treatment of hypovolemia. The
newer generations of starches
(ie, Voluven®) have several
potential advantages over
hetastarches: less plasma
accumulation, faster clearance

from the body, similar infusion
rates/volumes despite increased
clearance, less effect on coagulation
parameters, and the potential for
less use of replacement blood
products.
500-mL IV solution

Addition of Restriction:
Insulin U-500
Due to the potential for medication
errors, insulin U-500 will be restricted to the Diabetic Management Service.

Changes in Restrictions:
Meropenem (Merrem®)
Meropenem will now be restricted
to the following services and/or indications: pediatrics, infectious diseases, hematology/oncology, and in
those patients with suspected or
documented meningitis. The projected effective date is October 1,
2009.
Ketamine
A pre-printed order form was approved with dosing guidelines for
the use of ketamine continuous infusions outside of the ICU setting.
It will primarily be used in major
gastrointestinal/thoracic postoperative patients with high opioid requirements. The ketamine restriction will be updated to the following:
▪ Attending physicians from
the anesthesiology or
oral/maxillofacial surgery
services *OR*
▪ Patient location: emergency
department, ICU *OR*
▪ Outside of ICU setting:
Regional Anesthesia Pain Service (RASP) for use in gastroin-
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FORMULARY UPDATE FOR JUNE & JULY 2009
testinal/thoracic postoperative
patients with high opioid requirements. Order form will
be required.
The projected effective date is
October 1, 2009.

Line Extensions:

▪ Diphenhydramine (Benadryl )
25-mg tablets

▪ Gadobenate dimeglumine
▪

Exclusions:
6% hetastarch in LR (Hextend®)
Hextend® does not offer a
significant advantage over the
current hetastarch product.

▪
▪

Automatic Therapeutic ▪
Substitution (ATS) Protocol
▪
Addition:
Venlafaxine extended release
tablets
Venlafaxine immediate release
tablets are no longer used clinically and venlafaxine extended
release (generic) tablets are not
therapeutically equivalent (not
AB-rated) to brand Effexor® XR;
therefore, they cannot be automatically substituted without a
prescriber’s order. An automatic
substitution protocol has been developed for the conversion of orders for venlafaxine immediate
release and Effexor® XR tablets.

Bupropion hydrobromide
(Aplenzin®)
The ATS protocol for bupropion
was revised to include conversions for bupropion hydrobromide
(Aplenzin®) orders. These orders
will be switched to bupropion
hydrochloride sustained release
(SR) based on the dose, unless the
physician indicates “dispense as
written” and includes a clinical
justification on the order.

(Multihance®) 10-, 15-, and
20-mL vials
Diphenhydramine (Benadryl®)
elixir 12.5-mg/5-mL
unit-dose cups
Venlafaxine extended release
225-mg tablets
Esmolol (Brevibloc®) 2-g/100 mL
premix IV solution
(October 1, 2009)
Haloperidol (Haldol®) 2-mg/mL
(5 mL) unit-dose cups
Wheat dextrin powder
(Benefiber®) 3-g/3.5-g unit-dose
stick packs

Deletions:
▪ Pramoxine/hydrocortisone 1%
▪
▪
▪
▪
▪

Change in ATS Protocol:

®

▪
▪

▪

▪

(Epifoam®)
Gadobenate dimeglumine
(Multihance®) 50- and
100-mL vials
Albuterol (Ventolin®)
200-dose inhaler
Carmustine (Gliadel®)
7.7-mg wafer
Esmolol injection 10-mg/mL vial
and 1-g/100-mL premixed
IV solution (October 1, 2009)
Hydroxyzine pamoate (Vistaril®)
suspension
Theophylline sustained release
(Slo-Bid®) 125-, 200-, and 300mg capsules
Pantoprazole (Protonix®) 20- and
40-mg tablets; 40-mg injection;
2-mg/mL extemporaneous
suspension (October 1, 2009)
Lansoprazole (Prevacid®) 15- and
30-mg capsules; 3-mg/mL
extemporaneous suspension
(October 1, 2009)
Omeprazole (Prilosec®) 2-mg/mL
extemporaneous suspension
(October 1, 2009)

Intralipid Guidelines for Treatment of Anesthetic-induced
Cardiotoxicity
The P&T Committee approved the
guidelines for use of intralipid 20%
to reverse anesthetic-induced cardiotoxicity. The guidelines have
been posted in the various operating
room areas where the 500-mL bottles of intralipid 20% are stored.
Guidelines can also be found
online* on the Formulary and Drug
Information Resources Web page
and on the Clinician Order Forms
page under the OR section.
Policy C82: Formulary System
The Pharmacy Services policies
regarding drug recall and shortage
procedures will be formally added
to the C-82 policy. Additionally,
the criteria for medications
restricted to clinic use was clarified
to indicate that a patient must be
discharged from the hospital and
registered in an outpatient clinic
before a restricted medication will
be dispensed. Please refer to the
Formulary and Drug Information
Resources Web page for specific
criteria.
Teatment/reversal of Anticoagulant-associated Intracranial
Hemorrhage
Guidelines and a pre-printed order
form regarding the treatment of
anticoagulant-associated
intracranial hemorrhage using IV
vitamin K, factor IX complex
(Profilnine ® ), or fresh-frozen
plasma (FFP) were developed.
These will be available through the
clinician order forms site after
approval by the Forms Committee.

Intralipid Guidelines: http://www.musc.edu/pharmacyservices/medusepol/IntralipidGuidelinesCardioAnesth.pdf
Formulary and Drug Information Resources Web page: www.formularyproductions.com/musc

